Preferred Label : zanidatamab;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://ansm.sante.fr/tableau-acces-derogatoire/zanidatamab
2025
false
false
false
France
French
infusions, intravenous
zanidatamab
drug information
summary of product characteristics
package leaflet
adult
biliary tract neoplasms
HER2 positive biliary tract cancer
HER2/Neu Expression by Immunohistochemistry 3+
zanidatamab
Locally Advanced Bile Duct Carcinoma
Metastatic Bile Duct Carcinoma
Unresectable Bile Duct Carcinoma
guidelines for drug use

---
https://www.has-sante.fr/jcms/p_3563099/fr/ziihera-zanidatamab-cancer-des-voies-biliaires
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
HER2/Neu Expression by Immunohistochemistry 3+
adult
guidelines for drug use
infusions, intravenous
zanidatamab
evaluation of the transparency committee
biliary tract cancer
zanidatamab
biliary tract neoplasms

---
Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.